ZYX (zyxin) is an adhesion plaque protein that functions as a key regulator of focal adhesion assembly and cytoskeletal organization. At the molecular level, ZYX binds alpha-actinin and CRP proteins to target TES and ENA/VASP family members to focal adhesions, thereby promoting actin-rich structure formation and integrin-mediated signaling 1. ZYX participates in signal transduction pathways that couple adhesion stimulation to changes in gene expression, operating through FAK/PI3K/AKT and TGF-β signaling cascades 1. Dysregulated ZYX expression is implicated in multiple pathological conditions. In skin fibrosis—including systemic sclerosis, keloid, and localized scleroderma—ZYX overexpression in fibroblasts promotes pro-fibrotic gene expression and excessive collagen production via integrin-dependent FAK/PI3K/AKT and TGF-β activation; conversely, ZYX inhibition significantly alleviates fibrosis in animal models and human tissue explants 1. In glioblastoma multiforme, elevated ZYX expression correlates with tumor progression and poor patient prognosis, with ZYX promoting GBM invasive growth through upregulation of stathmin 1 (STMN1) 2. Additionally, ZYX upregulation contributes to pathological angiogenesis in moyamoya disease by promoting endothelial cell proliferation through AKT/GSK-3β/β-catenin signaling 3. These findings identify ZYX as a potential therapeutic target across fibrotic, neoplastic, and vascular pathologies.